KPIs & Operating Metrics(New)
Growth Metrics

Bristol Myers Squibb (BMY) Accumulated Expenses (2016 - 2019)

Historic Accumulated Expenses for Bristol Myers Squibb (BMY) over the last 11 years, with Q1 2019 value amounting to $5.9 billion.

  • Bristol Myers Squibb's Accumulated Expenses rose 530.48% to $5.9 billion in Q1 2019 from the same period last year, while for Mar 2019 it was $5.9 billion, marking a year-over-year increase of 530.48%. This contributed to the annual value of $6.5 billion for FY2018, which is 789.82% up from last year.
  • Per Bristol Myers Squibb's latest filing, its Accumulated Expenses stood at $5.9 billion for Q1 2019, which was up 530.48% from $6.5 billion recorded in Q4 2018.
  • Bristol Myers Squibb's 5-year Accumulated Expenses high stood at $6.5 billion for Q4 2018, and its period low was $1.8 billion during Q1 2015.
  • Its 5-year average for Accumulated Expenses is $4.8 billion, with a median of $5.1 billion in 2017.
  • As far as peak fluctuations go, Bristol Myers Squibb's Accumulated Expenses plummeted by 1031.55% in 2015, and later soared by 14070.35% in 2016.
  • Bristol Myers Squibb's Accumulated Expenses (Quarter) stood at $4.7 billion in 2015, then grew by 11.25% to $5.3 billion in 2016, then rose by 14.1% to $6.0 billion in 2017, then grew by 7.9% to $6.5 billion in 2018, then decreased by 9.75% to $5.9 billion in 2019.
  • Its last three reported values are $5.9 billion in Q1 2019, $6.5 billion for Q4 2018, and $5.9 billion during Q3 2018.